Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Multiple Myeloma, Newly Diagnosed”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07045909
What this trial is testing

Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)

Who this might be right for
De Novo Multiple MyelomaAnitocabtagene Autoleucel
PETHEMA Foundation 30
Large-scale testing (Phase 3)Not Yet RecruitingNCT07624513
What this trial is testing

D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM

Who this might be right for
Multiple Myeloma
Dana-Farber Cancer Institute 720
Testing effectiveness (Phase 2)Active Not RecruitingNCT06353022
What this trial is testing

Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Nantes University Hospital 103
Large-scale testing (Phase 3)Study completedNCT01091831
What this trial is testing

Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects

Who this might be right for
Multiple Myeloma
Fondazione EMN Italy Onlus 389
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07600151
What this trial is testing

Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma

Who this might be right for
Myeloma MultipleMyeloma
Universitätsklinikum Hamburg-Eppendorf 220
Post-approval studies (Phase 4)UnknownNCT01249690
What this trial is testing

Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Second Military Medical University 100
Testing effectiveness (Phase 2)Ended earlyNCT03733691
What this trial is testing

Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients

Who this might be right for
Newly Diagnosed Multiple Myeloma
Oncotherapeutics 19
Large-scale testing (Phase 3)Active Not RecruitingNCT01863550
What this trial is testing

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Who this might be right for
Plasma Cell Myeloma
ECOG-ACRIN Cancer Research Group 1,087
Testing effectiveness (Phase 2)Active Not RecruitingNCT04782687
What this trial is testing

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple MyelomaMyeloma MultipleKahler Disease+4 more
US Oncology Research 73
Testing effectiveness (Phase 2)Study completedNCT00540644
What this trial is testing

Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Attaya Suvannasankha 70
Testing effectiveness (Phase 2)Study completedNCT01160107
What this trial is testing

Revlimid And Prednisone Followed By Revlimid, Melphalan And Prednisone In Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
Fondazione EMN Italy Onlus 46
Not applicableStudy completedNCT01132833
What this trial is testing

Biomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving Chemotherapy

Who this might be right for
Multiple MyelomaPlasma Cell NeoplasmThromboembolism
UNC Lineberger Comprehensive Cancer Center 18
Testing effectiveness (Phase 2)Study completedNCT02203643
What this trial is testing

Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.

Who this might be right for
MULTIPLE MYELOMA (MM)
Mario Boccadoro 477
Testing effectiveness (Phase 2)UnknownNCT00742404
What this trial is testing

Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Oncotherapeutics 35
Testing effectiveness (Phase 2)WithdrawnNCT04258683
What this trial is testing

Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE

Who this might be right for
Multiple Myeloma
Canadian Myeloma Research Group
Not applicableEnded earlyNCT05276622
What this trial is testing

Patient and Care Partner Experiences Living With Multiple Myeloma (PaCE-MM)

Who this might be right for
Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center 64
Testing effectiveness (Phase 2)Active Not RecruitingNCT04653246
What this trial is testing

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

Who this might be right for
Multiple MyelomaNewly Diagnosed Multiple Myeloma (NDMM)Autologous Stem Cell Transplant
Jacob Laubach, MD 52
Testing effectiveness (Phase 2)Active Not RecruitingNCT00378105
What this trial is testing

Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Dana-Farber Cancer Institute 68
Testing effectiveness (Phase 2)UnknownNCT03641456
What this trial is testing

VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma

Who this might be right for
MyelomaNewly DiagnosedHigh Risk
Sun Yat-sen University 50
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07247097
What this trial is testing

ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma

Who this might be right for
Multiple MyelomaNewly Diagnosed Multiple MyelomaTransplant Ineligible+1 more
Massachusetts General Hospital 160
Next Page